C. Doggen

发表

Early cardiopulmonary resuscitation and use of Automated External Defibrillators by laypersons in out-of-hospital cardiac arrest using an SMS alert service.

Maarten J. IJzerman, A. Scholten, J. V. van Manen, 2011, Resuscitation.

The value of family history as a risk indicator for venous thrombosis.

F. Rosendaal, J. Eikenboom, F. V. D. van der Meer, 2009, Archives of internal medicine.

Coronary calcium scoring as first-line test to detect and exclude coronary artery disease in patients presenting to the general practitioner with stable chest pain: protocol of the cluster-randomised CONCRETE trial

P. V. van Ooijen, M. Oudkerk, G. Dinant, 2022, BMJ Open.

ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.

F. Rosendaal, D. Lane, C. Doggen, 2007, Blood.

VWF in MI 1 ADAMTS 13 , von Willebrand Factor and the Risk of Myocardial Infarction in Men

D. Lane, C. Doggen, J. Crawley, 2006 .

Endothelial function after ST-elevation myocardial infarction in patients with high levels of high-sensitivity CRP and Lp-PLA2: A substudy of the RESPONSE randomized trial.

R. Peters, C. von Birgelen, C. Doggen, 2017, Cardiovascular revascularization medicine : including molecular interventions.

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study.

Maarten J. IJzerman, J. W. Louwerenburg, M. Stoel, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2017, Journal of cardiology.

Prehospital paths and hospital arrival time of patients with acute coronary syndrome or stroke, a prospective observational study

M. Zwerink, C. Doggen, P. Brouwers, 2016, BMC Emergency Medicine.

Trauma team activation varies across Dutch emergency departments: a national survey

Maarten J. IJzerman, A. V. van Vugt, C. Doggen, 2015, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

Maarten J. IJzerman, J. W. Louwerenburg, C. von Birgelen, 2016, Heart and Vessels.

Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study

F. Rosendaal, C. Doggen, E. R. Pomp, 2008, Journal of thrombosis and haemostasis : JTH.

Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2016, American heart journal.

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

M. Stoel, C. von Birgelen, G. Linssen, 2018, Journal of the American Heart Association.

High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial

C. von Birgelen, G. Linssen, C. Schotborgh, 2018, Cardiovascular Drugs and Therapy.

Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial.

C. von Birgelen, G. Linssen, C. Schotborgh, 2021, Coronary artery disease.

Disfunción endotelial tras infarto de miocardio con elevación del segmento ST y evolución a largo plazo: un estudio con tonometría arterial periférica e hiperemia reactiva

Maarten J. IJzerman, R. Peters, B. Wagenaar, 2016 .

Endothelial Dysfunction After ST-segment Elevation Myocardial Infarction and Long-term Outcome: A Study With Reactive Hyperemia Peripheral Artery Tonometry.

Maarten J. IJzerman, R. Peters, C. von Birgelen, 2016, Revista espanola de cardiologia.

Serial assessment of endothelial function 1, 6, and 12 months after ST-elevation myocardial infarction

R. Peters, C. von Birgelen, Liefke C. van der Heijden, 2018, Heart and vessels.

New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.

M. Stoel, A. Roguin, C. von Birgelen, 2020, American heart journal.

Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.

F. Rosendaal, J. Rosing, C. Doggen, 2005, Human reproduction.

Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use

F. Rosendaal, C. Doggen, E. R. Pomp, 2008, American journal of hematology.

Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function.

R. Peters, M. Stoel, C. von Birgelen, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction

F. Rosendaal, J. G. van der Bom, C. Doggen, 2008, Journal of thrombosis and haemostasis : JTH.

Cardiovascular and demographic characteristics in whole blood and plasma donors: results from the Donor InSight study

I. Veldhuizen, F. Atsma, C. Doggen, 2011, Transfusion.

The Effect of Telehealth on Hospital Services Use: Systematic Review and Meta-analysis

W. V. van Harten, Laura Kooij, C. Doggen, 2020, Journal of medical Internet research.

Real-time monitoring of drug laboratory test interactions: a proof of concept

W. Verboeket-van de Venne, H. van der Sijs, C. Doggen, 2021, Clinical chemistry and laboratory medicine.

Old and new risk factors for upper extremity deep venous thrombosis – reply to a rebuttal

F. Rosendaal, C. J. van Rooden, C. Doggen, 2006 .

The Effect of Telehealth on Hospital Services Use: Systematic Review and Meta-analysis (Preprint)

W. V. van Harten, Laura Kooij, C. Doggen, 2020 .

The Diagnostic and Prognostic Value of Coronary Calcium Scoring in Stable Chest Pain Patients: A Narrative Review Der diagnostische und prognostische Wert der Koronarkalkmessung bei Patienten mit anhaltenden Brustschmerzen: Ein narrativer Überblick

G. Dinant, P. Harst, B. Kietselaer, 2022 .

The Diagnostic and Prognostic Value of Coronary Calcium Scoring in Stable Chest Pain Patients: A Narrative Review

P. V. van Ooijen, G. Dinant, P. van der Harst, 2022, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Variation in the time and day of onset of myocardial infarction and sudden death.

R. Beaglehole, J. van der Palen, C. Doggen, 1995, The New Zealand medical journal.

Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations

S. le Cessie, F. Rosendaal, C. Doggen, 2007, British journal of haematology.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial

M. Stoel, C. von Birgelen, G. Linssen, 2017, JAMA cardiology.

molecules in blood cells myocardial infarction and aberrant expression of inflammatory High throughput mRNA profiling highlights associations between

F. Rosendaal, C. Spek, C. Doggen, 2011 .

Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction.

P. Reitsma, F. Rosendaal, R. Bertina, 2009, Atherosclerosis.

Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men

F. Rosendaal, P. D. de Groot, C. Doggen, 2009, British journal of haematology.

Haplotypes encoding the factor VIII 1241Glu variation, factor VIII levels and the risk of venous thrombosis

F. Rosendaal, E. Bakker, R. Bertina, 2006, Thrombosis and Haemostasis.

Strenuous sport activities involving the upper extremities increase the risk of venous thrombosis of the arm

F. Rosendaal, K. V. van Stralen, C. Doggen, 2005, Journal of thrombosis and haemostasis : JTH.

Fibrinolysis and the risk of venous and arterial thrombosis

F. Rosendaal, P. D. de Groot, C. Doggen, 2007, Current opinion in hematology.

Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors

F. Rosendaal, M. den Heijer, S. Cannegieter, 2018, American journal of epidemiology.

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.

M. Stoel, C. von Birgelen, G. Linssen, 2014, International journal of cardiology.

The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.

F. Rosendaal, P. D. de Groot, C. Doggen, 2009, Seminars in thrombosis and hemostasis.

Added value of drug-laboratory test interaction alerts in test result authorisation

W. Verboeket-van de Venne, H. van der Sijs, C. Doggen, 2022, Clinical chemistry and laboratory medicine.

Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials

M. Stoel, A. Roguin, C. von Birgelen, 2020, International Journal of Cardiology.

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.

J. W. Louwerenburg, M. Stoel, I. Knottnerus, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2016, Revista espanola de cardiologia.

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

J. W. Louwerenburg, M. Stoel, I. Knottnerus, 2018, International journal of cardiology.

Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial

A. Roguin, C. von Birgelen, G. Linssen, 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Minor injuries as a risk factor for venous thrombosis.

F. Rosendaal, K. V. van Stralen, C. Doggen, 2008, Archives of internal medicine.

Proximal LAD Treated With Thin-Strut New-Generation Drug-Eluting Stents: A Patient-Level Pooled Analysis of TWENTE I-III.

M. Stoel, A. Roguin, C. von Birgelen, 2020, JACC. Cardiovascular interventions.

Thromboprophylaxis in cancer outpatients.

C. Doggen, 2008, Blood.

Recurrent Thrombosis and Survival After a First Venous Thrombosis of the Upper Extremity

F. Rosendaal, C. Doggen, L. Flinterman, 2008, Circulation.

The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

F. Rosendaal, C. Doggen, S. Osanto, 2005, Annals of Internal Medicine.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC: Cardiovascular Interventions.

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.

M. Stoel, C. von Birgelen, G. Linssen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis

F. Rosendaal, P. D. de Groot, C. Doggen, 2008, PLoS medicine.

Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome

J. W. Louwerenburg, M. Stoel, F. H. Man, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.

C. von Birgelen, G. Linssen, F. de Man, 2015, American heart journal.

Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk

F. Rosendaal, C. Doggen, L. Flinterman, 2010, British journal of haematology.

Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial

M. Stoel, C. von Birgelen, G. Linssen, 2017, Cardiology.

Association between cardiovascular medication and readmission in heart failure patients

K. Movig, C. Doggen, E. Heintjes, 2019 .

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: A patient-level pooled analysis of four randomized trials.

M. Stoel, A. Roguin, C. von Birgelen, 2022, Atherosclerosis.

Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2015, Clinical Research in Cardiology.

First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial.

A. Roguin, C. von Birgelen, C. Schotborgh, 2021, Circulation journal : official journal of the Japanese Circulation Society.

Three contemporary thin‐strut drug‐eluting stents implanted in severely calcified coronary lesions of participants in a randomized all‐comers trial

M. Stoel, F. H. Man, C. von Birgelen, 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Mechanisms of the Factor V Leiden Paradox

F. Rosendaal, K. V. van Stralen, C. Doggen, 2008, Arteriosclerosis, thrombosis, and vascular biology.

UvA-DARE ( Digital Academic Repository ) Experience with multiple control groups in a large population-based case-control study on genetic and environmental risk factors

S. Cessie, F. Rosendaal, J. Vandenbroucke, 2010 .

The effect of flight‐related behaviour on the risk of venous thrombosis after air travel

F. Rosendaal, S. Cannegieter, C. Doggen, 2009, British journal of haematology.

Continuous vital sign monitoring using a wearable patch sensor in obese patients: a validation study in a clinical setting

C. Groothuis-Oudshoorn, C. Doggen, B. Witteman, 2021, Journal of Clinical Monitoring and Computing.

Three‐year clinical outcome in all‐comers with “silent” diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug‐eluting stents: From the BIO‐RESORT Silent Diabetes study

M. Stoel, C. von Birgelen, G. Linssen, 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial.

M. Stoel, C. von Birgelen, G. Linssen, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

5 Factor V Leiden Mutation in Relation to Fecundity and Miscarriage in W omen with Venous Thrombosis

F. Rosendaal, C. Doggen, M. Heemskerk, 2007 .

Factor V Leiden mutation in relation to fecundity and miscarriage in women with venous thrombosis.

F. Rosendaal, C. Doggen, F. Helmerhorst, 2005, Human reproduction.

Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers.

F. Rosendaal, S. Cannegieter, C. Doggen, 2009, Blood.

Alcohol consumption is associated with a decreased risk of venous thrombosis

F. Rosendaal, C. Doggen, E. R. Pomp, 2007, Thrombosis and Haemostasis.

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men.

F. Rosendaal, P. D. de Groot, R. Derksen, 2009, Blood.

No effect of polymorphisms in prothrombotic genes on the risk of myocardial infarction in young adults without cardiovascular risk factors

P. Mannucci, F. Rosendaal, C. Doggen, 2005, Journal of thrombosis and haemostasis : JTH.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, The Lancet.

Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.

M. Stoel, A. Roguin, C. von Birgelen, 2020, JACC. Cardiovascular interventions.

Thin, Very Thin, or Ultrathin Strut Biodegradable- or Durable-Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.

M. Stoel, C. von Birgelen, G. Linssen, 2019, JACC. Cardiovascular interventions.

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.

M. Stoel, C. von Birgelen, G. Linssen, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Turbid plasma donations in whole blood donors: fat chance?

E. Slot, C. Doggen, W. D. de Kort, 2011, Transfusion.

Pain management in the emergency chain: the use and effectiveness of pain management in patients with acute musculoskeletal pain.

Maarten J. IJzerman, A. V. van Vugt, S. Berben, 2015, Pain medicine.

“It Really Is an Elusive Illness”—Post-COVID-19 Illness Perceptions and Recovery Strategies: A Thematic Analysis

J. van der Palen, C. Bode, H. Vonkeman, 2022, International journal of environmental research and public health.

Malignancies, prothrombotic mutations, and the risk of venous thrombosis.

F. Rosendaal, C. Doggen, S. Osanto, 2005, JAMA.

Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial disease.

M. Stoel, A. Roguin, C. von Birgelen, 2022, International journal of cardiology.

Final 5‐Year Report of the Randomized BIO‐RESORT Trial Comparing 3 Contemporary Drug‐Eluting Stents in All‐Comers

M. Stoel, C. von Birgelen, G. Linssen, 2022, Journal of the American Heart Association.

No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study.

F. Rosendaal, H. L. Vos, C. Doggen, 2007, Archives of internal medicine.

F9 Malmö, factor IX and deep vein thrombosis

P. Reitsma, J. Catanese, F. Rosendaal, 2009, Haematologica.

SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction.

P. Quax, F. Rosendaal, J. L. Hansen, 2011, American journal of hypertension.

The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study

F R Rosendaal, J. Vandenbroucke, F. Rosendaal, 2009, BMJ : British Medical Journal.

Current perspective of venous thrombosis in the upper extremity

F. Rosendaal, F. V. D. van der Meer, C. Doggen, 2008, Journal of thrombosis and haemostasis : JTH.

The tortuous history of the implementation of early ambulation after delivery

J. Vandenbroucke, K. V. van Stralen, C. Doggen, 2007, Journal of the Royal Society of Medicine.

High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells.

P. Reitsma, F. Rosendaal, C. Spek, 2005, Blood.

The HR2 Haplotype of Factor V Is not Associated with the Risk of Myocardial Infarction

F. Rosendaal, R. Bertina, H. Vos, 2000, Thrombosis and Haemostasis.

A nurse-initiated pain protocol in the ED improves pain treatment in patients with acute musculoskeletal pain.

Maarten J. IJzerman, A. V. van Vugt, S. Berben, 2016, International emergency nursing.

Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study.

P. Reitsma, F. Rosendaal, C. Doggen, 2013, Blood.

Hans C van Houwelingen, Frits R Rosendaal, H. V. van Houwelingen, 2006, PLoS medicine.

Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases

G. Linssen, J. van der Palen, K. Movig, 2020, PloS one.

Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

F. Rosendaal, S. le Cessie, P. D. de Groot, 2010, Blood.

Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men

F. Rosendaal, P. D. de Groot, C. Doggen, 2009, Haematologica.

Multiple SNP testing improves risk prediction of first venous thrombosis.

P. Reitsma, S. le Cessie, F. Rosendaal, 2012, Blood.

Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population.

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials

A. Roguin, C. von Birgelen, C. Schotborgh, 2021, Cardiovascular Diabetology.

Serum Lipid Levels and the Risk of Venous Thrombosis

B. Psaty, S. Heckbert, F. Rosendaal, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.

Felix Zijlstra, Jan-Henk E Dambrink, H. Suryapranata, 2003, Journal of the American College of Cardiology.

Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

Frits R Rosendaal, F. Rosendaal, C. Doggen, 2006, Blood.

A Mutation in the Thrombomodulin Gene, 127G to A Coding for Ala25Thr, and the Risk of Myocardial Infarction in Men

F. Rosendaal, H. Ireland, D. Lane, 1998, Thrombosis and Haemostasis.

Remote continuous monitoring with wireless wearable sensors in clinical practice, nurses perspectives on factors affecting implementation: a qualitative study

W. V. van Harten, Laura Kooij, C. Doggen, 2022, BMC Nursing.

Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.

F. Rosendaal, P. D. de Groot, C. Doggen, 2010, Blood.

Gene variants associated with deep vein thrombosis.

P. Reitsma, J. Catanese, F. Rosendaal, 2008, Journal of the American Medical Association (JAMA).

The Relationship Between Exercise and Risk of Venous Thrombosis in Elderly People

T. Lumley, A. Folsom, B. Psaty, 2008, Journal of the American Geriatrics Society.

Malmö , factor IX and deep vein thrombosis

P. Reitsma, J. Catanese, F. Rosendaal, 2009 .

F 9 Malmö , factor IX and deep vein thrombosis

P. Reitsma, J. Catanese, F. Rosendaal, 2022 .

Experience with multiple control groups in a large population-based case–control study on genetic and environmental risk factors

F. R. Rosendaal, S. le Cessie, F. Rosendaal, 2010, European Journal of Epidemiology.

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

J. W. Louwerenburg, M. Stoel, G. Linssen, 2016, The Lancet.

Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2014, American heart journal.

Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial.

H. D. de Koning, M. Oudkerk, D. Kuijpers, 2022, American heart journal.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, JACC. Cardiovascular interventions.

The impact of passive and active smoking on inflammation, lipid profile and the risk of myocardial infarction

C. Doggen, Carine J M Doggen, Ritienne Attard, 2017, Open Heart.

Polymorphisms in the protein C gene as risk factor for venous thrombosis

P. Reitsma, F. Rosendaal, C. Doggen, 2008, Thrombosis and Haemostasis.

Painful Discrimination in the Emergency Department: Risk Factors for Underassessment of Patients’ Pain by Nurses

Maarten J. IJzerman, M. Vollenbroek-Hutten, C. Doggen, 2017, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

Clinical outcome of patients with implantation of second‐generation drug‐eluting stents in the right coronary ostium: Insights from 2‐year follow‐up of the TWENTE trial

Maarten J. IJzerman, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines

R. Janssens, C. Doggen, H. B. Bernelot Moens, 2018, PloS one.

A Quantitative Analysis of Integrated Emergency Posts

Martijn R.K. Mes, Ingrid M. H. Vliegen, Carine J. M. Doggen, 2021 .

Detecting Patient Deterioration Early Using Continuous Heart rate and Respiratory rate Measurements in Hospitalized COVID-19 Patients

W. Harten, C. Doggen, M. Koning, 2023, Journal of Medical Systems.

Results of a survey among GP practices on how they manage patient safety aspects related to point-of-care testing in every day practice

Maarten J. IJzerman, R. Verheij, R. Geertsma, 2015, BMC Family Practice.

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.

C. von Birgelen, G. Linssen, C. Schotborgh, 2019, JAMA cardiology.

Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.

Maarten J. IJzerman, J. W. Louwerenburg, A. Maas, 2016, JACC. Cardiovascular interventions.

Bioresorbable Polymer‐Coated Orsiro Versus Durable Polymer‐Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial

A. Roguin, C. von Birgelen, G. Linssen, 2017, American heart journal.

Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.

M. Stoel, C. von Birgelen, G. Linssen, 2016, American heart journal.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

M. Stoel, A. Roguin, C. von Birgelen, 2018, The Lancet.

Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review.

C. Doggen, H. Koffijberg, Martijn J. Oude Wolcherink, 2023, PharmacoEconomics.

Three‐year clinical outcome after treatment of chronic total occlusions with second‐generation drug‐eluting stents in the TWENTE trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Geographic Distribution of the 20210 G to A Prothrombin Variant

P. Reitsma, D. Siscovick, F. Rosendaal, 1998, Thrombosis and Haemostasis.

Artificial intelligence in systematic reviews: promising when appropriately used

J. van der Palen, M. Brusse-Keizer, C. Doggen, 2023, BMJ Open.

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.

C. von Birgelen, K. Yadav, C. Doggen, 2016, International journal of cardiology.

Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased

F R Rosendaal, F. Rosendaal, R. Bertina, 1998 .

The impact of frequency, pattern, intensity, and type of alcohol consumption, and its combined effect with smoking on inflammation, lipid profile, and the risk of myocardial infarction

C. Doggen, P. Dingli, R. Farrugia, 2019, Journal of Public Health.

Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives.

S. Heckbert, N. Glazer, N. Smith, 2005, American journal of hypertension.

The indirect basophil activation test is a safe, reliable and accessible tool to diagnose a peanut allergy in children.

H. Savelkoul, C. Doggen, P. V. van Setten, 2022, The journal of allergy and clinical immunology. In practice.

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.

J. W. Louwerenburg, M. Stoel, I. Knottnerus, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Gene variants associated with deep vein thrombosis.

P. Reitsma, J. Catanese, F. Rosendaal, 2008, JAMA.

High coagulant factors & venous thrombosis.

C. Doggen, 2009, Blood.

Minor injuries as a risk factor for venous thrombosis.

F. Rosendaal, K. V. van Stralen, C. Doggen, 2008, Archives of internal medicine.

The impact of passive and active smoking on inflammation, lipid profile and the risk of myocardial infarction

C. Doggen, P. Dingli, R. Farrugia, 2017, Open Heart.

Is a preoperative multidisciplinary team meeting (cost)effective to improve outcome for high-risk adult patients undergoing noncardiac surgery: the PREPARATION study—a multicenter stepped-wedge cluster randomized trial

R. Poolman, C. Doggen, P. Noordzij, 2023, Trials.

SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction.

P. Quax, F. Rosendaal, J. L. Hansen, 2011, American journal of hypertension.

Thromboprophylaxis in cancer outpatients.

C. Doggen, 2008, Blood.

Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.

Maarten J. IJzerman, C. von Birgelen, G. Linssen, 2016, Revista espanola de cardiologia.

Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized comparison of biodegradable polymer and durable polymer drug-eluting stents in an all comers population trial.

C. von Birgelen, G. Linssen, C. Schotborgh, 2020, Coronary artery disease.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

First myocardial infarction in patients with premature coronary artery disease: insights into patient characteristics and outcome after treatment with contemporary stents

A. Roguin, C. von Birgelen, G. Linssen, 2023, European heart journal. Acute cardiovascular care.

Impact of premature coronary artery disease on adverse event risk following first percutaneous coronary intervention

C. von Birgelen, G. Linssen, C. Schotborgh, 2023, Frontiers in cardiovascular medicine.

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Three‐year clinical outcome after treatment of chronic total occlusions with second‐generation drug‐eluting stents in the TWENTE trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Ten-year mortality after treating obstructive coronary atherosclerosis with contemporary stents in patients with or without concomitant peripheral arterial disease.

M. Stoel, C. von Birgelen, G. Linssen, 2024, Atherosclerosis.

Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?

C. Doggen, H. Koffijberg, X. Pouwels, 2023, Expert review of pharmacoeconomics & outcomes research.

Physical and mental fatigue in post-COVID syndrome and their associations over time: A small-sample ESM-study to explore fatigue, quality of sleep and behaviours.

J. van der Palen, P. T. ten Klooster, C. Bode, 2022, Journal of psychosomatic research.